Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients With Mild to Moderate Atopic Dermatitis

NCT03107611 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT03107611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03107611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients With Mild to Moderate Atopic Dermatitis
Lead sponsor
Mylan Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2016
Completion date
May 15, 2017
Enrollment
654 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis